The GLP-1 receptor analogue Victoza® (liraglutide) significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial, Novo Nordisk has announced.
The drug significantly reduces the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13 per cent vs placebo (95 per cent confidence interval [CI]: 0.78; 0.97, p=0.01), in addition to standard of care in 9,340 adults with type 2 diabetes at high CV risk.
To read more, click here.